Clinical trial Recruiting at 1 site Observational Ages 40 to 69 Women only

Assessing breast cancer risk using ultrasound in women with dense breasts

Official title: Association of Sonographic Glandular Tissue Component With Breast Cancer Risk Among Women With Dense Breasts: A Prospective, Multinational Validation Study

Run by Seoul National University Hospital · NCT05460975 · Data updated 2026-11-12

This study is testing if using ultrasound to measure glandular tissue in women with dense breasts can help predict their risk of developing breast cancer.

More Breast Cancer trials

Quick facts

Study typeObservational
Ages40 Years to 69 Years
SexWomen only
Enrollment16164 (estimated)
SponsorSeoul National University Hospital
Academic / other
Locations1 site (Seoul)
StatusRecruiting
StartedNovember 1, 2022
Main results expectedMarch 30, 2026
Study endsDecember 30, 2031
Registry record updatedJune 4, 2024
Trial IDNCT05460975 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women aged 40 to 70 with dense breasts (BI-RADS categories C and D) and no history of breast cancer.

Probably not a fit

Patients with a history of breast cancer, certain surgical histories, or who are currently pregnant or breastfeeding may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This international multicenter study aims to validate the association between sonographic glandular tissue component (GTC) and the risk of developing breast cancer in women with dense breasts. It will enroll 16,164 women aged 40 to 70 who have dense breast tissue as classified by mammography. The study will assess the amount of glandular tissue relative to fibrous stroma using breast ultrasound and will track participants for breast cancer diagnosis over time. The goal is to determine if GTC can provide additional risk assessment information beyond existing factors.

Why it matters

Potential benefit: If successful, this study could enhance breast cancer screening and risk assessment for women with dense breasts.

How similar studies have gone: Previous studies have shown a potential link between sonographic GTC and breast cancer risk, but this study aims to prospectively validate those findings on a larger scale.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria

1. be ≥ 40 and \<70 years old at time of US
2. No history of previous breast cancer including DCIS
3. have dense breasts (BI-RADS category C and D on mammography performed within 12 months of breast US) and negative/benign BI-RADS assessment categories on mammography (BI-RADS 1, 2)
4. undergoing screening breast US using either automated or handheld device

Exclusion Criteria

1. history of bilateral prophylactic mastectomy
2. history of bilateral foreign body injection
3. history of bilateral breast implants
4. history of bilateral breast reduction surgery or surgical excision
5. currently pregnant or breast feeding in the preceding 6 months
6. Known distant metastasis from other primary cancer

Where it's running

  • Seoul National University Hospital
    Seoul, South Korea
    Recruiting

Study contacts

  • Principal investigator: Woo Kyung Moon, MD, PhD — Seoul National University Hospital
  • Study coordinator: Woo Kyung Moon, MD, PhD
  • Email: moonwk1963@gmail.com
  • Phone: +82220722584

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.